On Being with Krista Tippett

"Psychedelic Science and Radical Healing" — Gül Dölen with Krista Tippett

The conversation between Krista Tippett and neuroscientist Gül Dölen explores how modern psychedelic research is reshaping our understanding of brain plasticity and mental‑health treatment. Dölen, who leads the Dolan Lab at UC Berkeley, recounts her interdisciplinary journey—from a self‑designed major in neuroscience, linguistics and philosophy to MD‑PhD work on autism—and how a class on drugs, brain and behavior sparked a lifelong focus on psychedelics. Central to the discussion is the discovery of a “critical period” for social learning that can be reopened in adulthood with compounds such as MDMA, psilocybin and ibogaine. Unlike SSRIs, which merely adjust serotonin levels, psychedelics appear to trigger rapid neuroplasticity, allowing a few guided sessions to produce durable behavioral change. The speakers stress that therapeutic outcomes hinge on set and setting, with clinical environments producing empathogenic, “heart‑opening” effects distinct from recreational use. Dölen cites her lab’s work on octopuses and the historic imprinting experiments of Conrad Lorenz to illustrate how critical periods have long been recognized across species. She notes that over 7,000 papers have examined these mechanisms, earning three Nobel Prizes, and that current psychedelic trials are revealing how brief drug exposure combined with psychotherapy can rewrite maladaptive social circuits. If these findings hold, they could upend the pharmaceutical model that relies on chronic, patentable medications and multi‑billion‑dollar phase‑III trials. Investors, clinicians, and regulators must grapple with a paradigm where short‑course, non‑patentable treatments deliver long‑term remission, prompting new funding structures and regulatory pathways for mental‑health care.